Relapsed/Refractory Follicular Lymphoma research hub
6 indexed studies · 1 currently recruiting
- active not recruitingPHASE3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
This study is testing new treatments for two types of lymphoma, follicular and marginal zone lymphoma, when they have come back or not responded to previous treatment. It compares a drug called zanubrutinib combined with other medicines against a standard treatment to see which works best.
United States · Argentina · Australia - ongoing, recruitingTherapeutic confirmatory (Phase III)
A pivotal phase 3 clinical trial to assess the diagnostic performance and safety of [68Ga]Ga-PentixaFor ([68Ga]Ga-PTF), a positron emission tomography (PET) imaging agent, versus [18F]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma (MZL) exemplary for CXCR4-positive malignant lymphomas: a prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial (LYMFOR).
This study compares two types of body scans for people with marginal zone lymphoma (a type of cancer). It aims to see if a newer scan ([68Ga]Ga-PentixaFor PET/CT) is better or as good as the standard scan ([18F]FDG PET/CT) at finding cancer cells in the body.
Germany · Italy · Spain - active not recruitingPHASE2
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
This study is testing a new combination of medicines, Copanlisib and Rituximab, for a type of blood cancer called Marginal Zone Lymphoma (MZL). It aims to see if this chemotherapy-free treatment is effective and has fewer side effects than current options, especially for older patients.
Austria · Germany - recruitingPHASE1, PHASE2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
This study is testing a new medicine called BGB-16673 for people with certain types of B-cell cancers, like lymphoma or chronic leukaemia. It aims to find the right dose and see how well it works and if it's safe. It's an early-stage trial.
United States · Australia · Brazil - active not recruitingPHASE2
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
This study looks at a new drug, Iopofosine I-131, for people with certain B-cell cancers like Waldenstrom, myeloma, or lymphoma, who haven't responded well to other treatments. It aims to see how safe and effective this new approach is.
United States · Australia · Brazil - active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This study looks at a new drug, tafasitamab, alongside standard treatments for follicular lymphoma and marginal zone lymphoma that have come back or not responded well. It aims to see if adding this new drug works better than the usual treatment alone.
United States · Australia · Austria